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Abstract
Human cytomegalovirus (HCMV) is an important opportunistic pathogen that infrequently causes disease in individuals with mature
immune systems. The HCMV US3 gene encodes a 22-kDa protein that interferes with immune recognition of virally infected cells. The
22-kDa US3 protein binds to major histocompatibility complex (MHC) class I complexes, retaining them in the endoplasmic reticulum (ER),
thereby decreasing the presentation of viral antigen to cytotoxic T cells. Our studies demonstrate that correct folding of the ER lumenal
domain of the US3 protein is essential, but insufficient for interactions with MHC class I complexes. We demonstrate a requirement for the
transmembrane domain of the 22-kDa US3 protein, confirming the results of others, and also show that the cytosolic carboxyl-terminal tail
influences the function of the protein. Anchoring of the ER-lumenal immunoglobulin-like fold of the US3 protein to the membrane of the
endoplasmic reticulum is critical for the binding and retention of MHC class I complexes.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
Human cytomegalovirus (HCMV) is a very common
infection, with 50–90% of adults having evidence of infec-
tion (Britt and Alford, 1996). Following infection, the virus
becomes latent in the infected host. Despite the high infec-
tion rate, HCMV is primarily an opportunistic pathogen,
causing clinically significant disease in people with com-
promised or immature immune systems. The success of
HCMV as an opportunistic pathogen is believed to be due,
in part, to the large number of proteins encoded by the virus
that manipulates immune recognition of infected cells.
HCMV encodes several proteins that interfere with ma-
jor histocompatibility complex (MHC) class I antigen pre-
sentation to cytotoxic T cells (Hengel and Koszinowski,
1997; Lorenzo et al., 2001). Proteins encoded by the HCMV
genes US2, US3, US6, US10, and US11 interfere with
immune recognition of virally infected cells. The US3 gene
is involved in retaining MHC class I complexes in the
endoplasmic reticulum (ER) (Ahn et al., 1996; Jones et al.,
1996). The proteins encoded by US2 and US11 bind to
MHC class I complexes and cause the complexes to be
translocated from the ER to the cytosol, where they are
degraded (Jones et al., 1995; Wiertz et al., 1996a, 1996b).
The US6 protein blocks the transporter for antigen presen-
tation, inhibiting the maturation of MHC class I complexes
(Sadasivan et al., 1996; Hengel and Koszinowski, 1997;
Ahn et al., 1997). US10 delays the normal trafficking of the
MHC class I complexes out of the ER (Furman et al., 2002).
In addition to interfering with MHC class I antigen presen-
tation, US2 and US3 proteins also interfere with MHC class
II antigen presentation (Tomazin et al., 1999; Hegde et al.,
2002; Johnson and Hegde, 2002).
Analysis of the crystal structure of the US2 protein
(pUS2) identified an immunoglobulin (Ig)-like fold in the
ER-lumenal domain of the protein (Gewurz et al., 2001a).
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The Ig-like fold is composed of seven -strands and con-
tains a conserved disulfide bond that links -strands G and
A. Regions of the -strands C, F, and G contact the MHC
molecule, HLA-A2. Structure-based sequence alignment
suggested that other HCMV proteins, including those en-
coded by the US3, US6, US7, US8, US9, US10, and US11
genes, would also contain similar Ig-like folds, predicted to
be involved in adhesion to MHC class I complexes. The
binding of US2, US3, US6, US8, US10, and US11 proteins
to MHC class I complexes supports this hypothesis (Wiertz
et al., 1996b; Jones et al., 1996; Lorenzo et al., 2001; Rehm
et al., 2002; Tirabassi and Ploegh, 2002).
The mechanism used by the US3 gene to retain MHC
class I complexes in the ER is incompletely understood. The
US3 gene is expressed at immediate-early times postviral
infection and encodes three related proteins of 22, 17, and
3.5 kDa (Weston, 1988; Tenney et al., 1993; Liu et al.,
2002). Only the 22-kDa protein (pUS322kDa) is able to retain
MHC class I complexes in the ER (Ahn et al., 1996; Jones
et al., 1996; Liu et al., 2002). pUS322kDa is classified as a
resident ER protein and comprises a signal peptide, an
ER-lumenal domain, a transmembrane domain, and a car-
boxyl-terminal cytosolic tail. The transmembrane domain is
essential for retention of MHC class I complexes in the ER
(Lee et al., 2000; Gruhler et al., 2000), while the ER-
lumenal domain was determined to be sufficient for intra-
cellular localization. Studies by Lee et al. (2003) identified
amino acids in the ER-lumenal domain essential for ER
localization of the protein, suggesting that the localization
signal is spatially complex. Additional analyses using an
HA-tagged version of pUS322kDa and a monoclonal anti-
body to the HA tag demonstrated that at least some of the
pUS322kDa traffics through the Golgi (Gruhler et al., 2000).
Gruhler et al. (2000) propose that pUS322kDa transiently
associates with MHC class I complexes and is then pro-
cessed through the Golgi and degraded, blocking the for-
ward transport of the MHC class I complexes. We per-
formed additional studies to further clarify the contributions
of the different domains of pUS322kDa to the binding and
retention of MHC class I complexes in the ER.
Results
The presence of an Ig-like fold is insufficient for binding
to MHC class I complexes
Two of the proteins encoded by the US3 gene,
pUS322kDa and pUS317kDa, share an identical amino-termi-
nal peptide sequence of 134 amino acids, which include the
signal peptide and predicted Ig-like fold domain (Tenney et
al., 1993; Gewurz et al., 2001a). The most significant dif-
ference between the two US3 proteins is the presence of a
transmembrane domain in pUS322kDa. Previous work dem-
onstrated that the two proteins have functional differences
as well, with pUS317kDa unable to retain MHC class I
molecules in the ER (Liu et al., 2002). Although pUS317kDa
is unable to retain MHC class I complexes in the ER, the
protein contains the predicted Ig-like fold and potentially
could associate with MHC class I complexes. We investi-
gated the interaction of pUS317kDa with MHC class I com-
plexes using coimmunoprecipitation.
Cell lines that inducibly expressed either the 22- or the
17-kDa US3 proteins were generated by infecting HeLa
tet-on cells with retroviruses that encode pUS322kDa or
pUS317kDa under the control of a doxycycline-inducible
promoter. Expression of the US3 proteins was induced and
proteins were metabolically labeled with [35S]-methionine.
Subsequent to protein labeling, cells were lysed using dig-
itonin, and MHC class I complexes were immunoprecipi-
tated using monoclonal antibody W6/32, which recognizes
MHC class I complexes. As shown previously by Jones et
al. (1996) and Ahn et al. (1996), pUS322kDa coprecipitated
with MHC class I complexes (Fig. 1A, lanes 2 and 3). In
contrast, no coprecipitating protein was detected in cells
expressing only the 17-kDa protein (Fig. 1A, lane 4), con-
firming and extending published results (Jones et al., 1996).
Thus, despite containing a predicted Ig-like fold identical to
that of pUS322kDa, the 17-kDa protein did not associate with
MHC class I complexes. These data suggest that either the
17-kDa protein does not form an Ig-like fold or that the
Ig-like fold, in the absence of a transmembrane domain, is
insufficient for forming associations with MHC class I com-
plexes.
Identification of regions of the pUS322kDa protein involved
in MHC class I complex binding and ER retention
pUS322kDa binds to and retains MHC class I complexes
in the ER (Ahn et al., 1996; Lee et al., 2000; Jones et al.,
1996). Lee et al. (2000) and Gruhler et al. (2000) identified
the transmembrane domain of the 22-kDa protein as critical
for ER retention of MHC class I complexes and further
concluded that the carboxyl-terminal tail had only a minor
role in the function of the US3 protein. We extended their
results by analyzing the ability of variant forms of
pUS322kDa to bind and retain MHC class I complexes in the
ER. The variants of pUS322kDa that were analyzed included
a protein with the carboxyl-terminal tail deleted, a protein
with the carboxyl-terminal tail and transmembrane domain
deleted, a protein with a cys44 to ser44 substitution, and a
protein with lysine124,125 to valine124,124 substitutions. The
cysteine-to-serine mutation was predicted to disrupt folding
of the Ig-like domain by preventing the formation of the
disulfide bond linking -strands G and A. The lysine-to-
valine substitutions alter the predicted isoelectric focusing
point of the lumenal domain of the protein from 6.69 to
6.20, and specifically alter the charge of -stand G, which is
important in binding MHC complexes (Gewurz et al.,
2001a).
Binding of the pUS322kDa variants to MHC class I com-
plexes was analyzed using coprecipitation experiments as
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described above. Expression of the US3 proteins was in-
duced, and MHC class I complexes were immunoprecipi-
tated following radiolabeling. Analysis of the cell lines
demonstrated that similar levels of US3 expression were
induced in all cell lines (data not shown). As discussed
above, pUS322kDa coprecipitated with MHC class I com-
plexes. Deletion of the carboxyl-terminal tail (COOH)
reduced but did not eliminate the association of the US3
protein with MHC class I complexes (Fig. 1A, lane 5). In
contrast, deletion of the carboxyl-terminal tail and trans-
membrane domain (TM) or mutation of cys44 eliminated
the interaction between MHC class I complexes and
pUS322kDa (Fig. 1A, lanes 6 and 7). Substitution of two
valine residues for two lysine residues in the ER lumenal
domain of the US3 protein reduced but did not eliminate the
interaction between MHC class I complexes and pUS322kDa
(Fig. 1A, lane 8). Binding of the COOH-tail US3 protein
variant or the lysine124,125 mutant to MHC class I com-
plexes was reduced four to five fold, compared to wild-type
pUS322kDa (Figs. 1A and B).
In addition to assays for binding, ER retention of MHC
class I complexes by the pUS322kDa variants was also in-
vestigated. Following the induction of US3 expression, pro-
teins were radiolabeled, and cells were then either immedi-
Fig. 1. Binding of US3 proteins to MHC class I molecules. (A) Stable cell lines lysed with 1% digitonin following metabolic labeling; MHC class I complexes
were immunoprecipitated with monoclonal antibody W6/32. Lane 1, control cells that contain no US3 sequences; lanes 2 and 3, cells expressing pUS322kDa;
lane 4, cells expressing pUS317kDa; lane 5, cells expressing pUS322kDa with the COOH-terminal end deleted; lane 6, cells expressing a variant of pUS322kDa
that lacks the transmembrane domain and the carboxyl-terminal end; lane 7, cells expressing pUS322kDa with the cysteine at position 44 mutated to serine;
and lane 8, cells expressing pUS322kDa with the two lysine residues in the predicted G- sheet mutated to valines. HC, heavy chain; US3, US3 protein variants;
2M, 2 microglobulin. (B) Quantification of the US3 protein bound to the MHC class I complexes. The US3 protein coprecipitating with the MHC class
I heavy chains was quantified by scanning the results depicted above, normalizing to the amount of heavy chain (HC) precipitated.
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ately lysed, or lysed following a chase period with
nonradioactive amino acids. MHC class I complexes were
immunoprecipitated with monoclonal antibody W6/32; im-
munoprecipitates were divided into two aliquots, and either
mock-treated or treated with endoglycosidase H to remove
incompletely processed oligosaccharides. Results from
these experiments are shown in Fig. 2.
In all of the cell lines examined, following the 30-min
labeling period, the majority of MHC class I complexes
were sensitive to endoglycosidase H treatment (Fig. 2). In
the parental cells, a 2-h chase with nonradioactive amino
acids was sufficient for maturation of the oligosaccharides
on the majority of MHC class I heavy chains, as indicated
by resistance to endoglycosidase H treatment and corre-
sponding to the processing and maturation events that occur
in the Golgi apparatus (Fig. 2, compare lanes 3 and 4).
Expression of pUS322kDa prevented oligosaccharide matura-
tion on the majority of the MHC class I complexes, as reflected
by continued sensitivity to endoglycosidase H following the
chase period (Fig. 2, lanes 5–8) and as previously shown (Liu
et al., 2002; Ahn et al., 1996; Jones et al., 1996).
Proteins unable to bind MHC class I complexes were not
expected to have any effect on the maturation of MHC class
I complexes. Expression of the 17-kDa US3 protein did not
alter the maturation of MHC class I complexes as predicted
(Fig. 2, lanes 9–12) (Liu et al., 2002). Similarly, expression
of pUS322kDa with the transmembrane region deleted or
with cysteine44 mutated also had no impact on the matura-
tion of MHC class I complexes (Fig. 2, lanes 13–16 and
lanes 25–28).
Versions of pUS322kDa with the carboxyl-terminal tail
deleted or with substitutions for lysine124,125 bind to MHC
class I complexes with decreased efficiency compared to the
wild-type protein (Fig. 1), suggesting that these versions of
pUS322kDa would delay maturation of MHC class I com-
plexes, albeit at a lower efficiency. Indeed, pUS322kDa with
valine substitutions for lysine124,125 delayed the maturation
of MHC class I complexes with a reduced efficiency (Fig. 2,
compare lanes 5–8 with lanes 21–24). Surprisingly,
pUS322kDa lacking the carboxyl-terminal tail was no longer
able to delay MHC class I complex maturation (Fig. 2, lanes
17–20). These data demonstrate that the carboxyl-terminal
tail contributes to the ability of pUS322kDa to retain MHC
class I complexes in the ER. Fig. 3 summarizes the MHC
class I complex binding and ER retention for pUS322kDa
variants.
Fig. 2. Retention of MHC class I heavy chains in the endoplasmic reticulum. Metabolically labeled cells were either lysed immediately following labeling
(pulse) or incubated in the absence of labeled amino acids prior to lysis (chase). MHC class I complexes were immunoprecipitated using monoclonal antibody
W6/32. Immunoprecipitates were either mock-treated () or treated with endoglycosidase H () to remove immature oligosaccharides. Lanes 1–4, parental
cells; lanes 5–8, cells expressing pUS322kDa; lanes 9–12, cells expressing pUS317kDa; lanes 13–16, cells expressing a variant of pUS322kDa that lacks the
transmembrane and carboxyl-terminal tail domains; lanes 17–20, cells expressing a variant of pUS322kDa lacking the carboxyl-terminal cytosolic tail; lanes
21–24, cells expressing pUS322kDa with two valine residues substituted for two lysine residues; and lanes 25–28, cells expressing pUS322kDa with a
substitution for one of the cysteine residues. MHC, heavy chain; 2M, 2-microglobulin.
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Intracellular localization of the US3 proteins
Deletion of the carboxyl-terminal tail of the US3 protein
as well as amino acid substitutions for cysteine44 and ly-
sine124,125 residues altered the ability of pUS322kDa to bind
to and retain MHC class I complexes in the ER. The failure
of the protein variants to bind and retain MHC class I heavy
chains could result from a decreased ability to physically
associate with MHC class I heavy chains, or alternatively,
from a change in the intracellular location of the protein.
The intracellular location of the pUS322kDa variants was
determined using fluorescence microscopy and enhanced
green fluorescent protein (EGFP)-tagged US3 proteins, with
the US3 proteins fused, in-frame, at the carboxyl-terminal
end to EGFP. Following the transfection of cells with US3-
EGFP expression plasmids, cell nuclei were stained with
DAPI and the ER was visualized using a monoclonal anti-
body to protein disulfide isomerase (a resident ER protein).
In these experiments, pUS322kDa-EGFP localized predomi-
nantly to the ER (Fig. 4, wt), as previously reported (Ahn et
al., 1996; Jones et al., 1996; Gruhler et al., 2000). The
merged images of pUS322kDa-EGFP and PDI remained pre-
dominantly green, presumably due to the overexpression of
the EGFP-fusion protein as well as the processing of the
US3 protein through the Golgi (Gruhler et al., 2000). Ex-
pression of pUS3TM as an EGFP fusion protein resulted
in green fluorescence in the ER, the Golgi, and in small
intracytoplasmic organelles, suggestive of processing
through secretory vesicles, similar to the localization of
pUS317kDa (Fig. 4) (Liu et al., 2002). Deletion of the car-
boxyl-terminal tail of pUS322kDa resulted in predominantly
ER localization with a small amount of the protein located
in intracytoplasmic vesicles (Fig. 4, compare wt, TM, and
COOH). The protein with the transmembrane deletion
lacks two amino acids of the transmembrane domain and the
entire carboxyl-terminal tail. The change in intracellular
location of the mutant protein is presumed to be a result of
the shortened stop-transfer sequence and/or removal of the
charged amino acids in the carboxyl-terminal tail, both of
which have been identified as signals for the interruption of
protein translocation (Kuroiwa et al., 1990; Falcone et al.,
1999).
The versions of pUS322kDa with amino substitutions lo-
calized to the ER in a pattern virtually identical to the
wild-type protein (Fig. 4). The localization data demonstrate
that the transmembrane domain and carboxyl-terminal tail
are important for localizing and retaining pUS322kDa in the
ER. The proteins containing amino acid substitutions had an
intracellular distribution identical to the wild-type
pUS322kDa, demonstrating that their inability to bind to
and/or efficiently retain MHC class I complexes in the ER
was not the result of a change in intracellular location.
Discussion
The HCMV US3 gene is transcribed into alternatively
spliced RNAs that encode different but related proteins. The
largest of the US3 proteins, a 22-kDa protein, retains MHC
class I molecules in the ER (Liu et al., 2002). pUS322kDa
comprises an ER-lumenal amino-terminal portion, a trans-
membrane domain, and a short carboxyl-terminal cytosolic
tail. Our results presented here demonstrate that the differ-
ent protein domains contribute to the ability of the protein to
interfere with MHC class I antigen presentation.
The correct folding of the ER-lumenal domain of
pUS322kDa is required for binding to MHC class I com-
plexes. Substitution of two neutral amino acids for two
charged amino acids (lys124,125) in a portion of the ER-
lumenal domain which is not predicted to contact MHC
class I heavy chains (Gewurtz et al., 2001a) reduced the
binding of pUS322kDa to MHC class I complexes. This
suggests that the charge of the lumenal domain is important
for functional activity of the US3 protein. Elimination of the
intramolecular disulfide bond in the ER lumenal domain of
pUS322kDa abolished the binding of pUS322kDa to MHC
class I complexes. Both of these point mutants had an
intracellular location similar to that of the wild-type protein
and support the prediction that the immunoglobulin-like
fold in the ER-lumenal domain of pUS322kDa is important
for binding and retaining MHC class I complexes in the ER
(Gewurz et al., 2001a). This confirms the results of Lee et
al. (2000), who failed to detect pUS322kDa MHC class I
complex associations using a version of pUS322kDa contain-
ing the US3 transmembrane and carboxyl-terminal regions
fused to a heterologous ER-lumenal domain.
The pUS322kDa transmembrane domain has been re-
ported as essential for the immune evasion functions of the
protein (Lee et al., 2000). Our results demonstrated that
deletion of the transmembrane domain abolishes the ability
of pUS322kDa to interact with or retain MHC class I heavy
chains in the ER. In contrast to the work of Lee et al. (2000,
2003), in our hands, deletion of the transmembrane domain
Fig. 3. Diagram of the US3 22 and 17-kDa proteins. The black rectangle
represents the signal peptide; the open rectangle represents the ER lumenal
portion of pUS322kDa; the dark gray rectangle represents the transmem-
brane region; the light gray rectangle represents the cytosolic carboxyl
terminal tail; the cross hatched portion of pUS317kDa represents a stretch of
amino acids found only in pUS317kDa. The vertical arrows indicate the
positions of the open reading frame truncations. The horizontal arrows
represent the coils of the immunoglobulin-like region (Gewurz et al.,
2001a). The C and KK indicate the positions of the amino acid substitu-
tions. The involvement of each of the regions in binding to and ER
retention of MHC class I complexes is indicated.
357Y. Zhao, B.J. Biegalke / Virology 315 (2003) 353–361
Fig. 4. Intracellular localization of pUS322kDa variants. The US3 open reading frame was expressed as a fusion protein with EGFP (GFP-tag) and visualized
using fluorescence microscopy. Nuclei were stained with DAPI; the endoplasmic reticulum was stained with an antibody to protein disulfide isomerse (PDI).
The merged images are a composite of the red, green, and blue fluorescent images. Wt, pUS322kDa; TM, pUS322kDa lacking the transmembrane and
carboxyl-terminal tail; COOH, pUS322kDa lacking only the carboxyl-terminal tail; KK 3 VV, pUS322kDa with two amino acid substitutions; and C 3 S,
pUS322kDa with a cysteine-to-serine substitution.
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altered the intracellular location of the pUS322kDa, with the
protein lacking the transmembrane domain exhibiting a lo-
calization pattern suggestive of processing through the se-
cretory pathway. Our ability to detect pUS322kDa in secre-
tory vesicles is most likely due to an increased ability to
detect EGFP-tagged proteins when expressed at a high
level, in contrast to the immunocytology experiments per-
formed using polyclonal antisera to pUS322kDa (Lee et al.,
2000) or to the experiments performed using moderate ex-
pression levels of US3-EGFP (Lee et al., 2003). We have
observed similar intracytoplasmic vesicles using antibodies
to US3 proteins (data not shown); our data, along with the
results of Gruhler et al. (2000), suggest that processing and
localization of the US3 proteins is complex.
Substitution of a heterologous transmembrane domain
for the US3 transmembrane domain was unable to restore
the functional activity of the protein (Lee et al., 2000),
suggesting that localization of pUS322kDa to the membrane
of the ER alone is insufficient for MHC Class I molecule
retention. However, the heterologous transmembrane do-
main used to substitute for the US3 transmembrane domain
was 60 amino acids in length, significantly longer than the
19-amino-acid transmembrane domain of the US3 protein.
Substitution of the large heterologous transmembrane do-
main may have resulted in structural alterations that im-
pacted the ability of the ER-lumenal domain to form an
Ig-like fold and interact with MHC class I heavy chains.
Further studies, including site-directed mutagenesis of the
pUS322kDa transmembrane domain are needed to clarify the
contributions of this region to the immune evasion function
of the protein.
In summary, we suggest that the ER-lumenal domain
mediates interactions with MHC class I complexes while
the transmembrane domain and cytoplasmic tail function to
localize pUS322kDa in the membrane of the ER. In the
absence of correct localization, pUS322kDa is unable to bind
to MHC class I complexes, suggesting that colocalization in
the ER membrane is critical for the protein–protein interac-
tions. Alterations in the intracellular location of pUS322kDa
correlated directly with a decreased ability to associate with
and retain MHC class I complexes in the ER. The require-
ment of colocalization for protein–protein interactions sug-
gests that ER components facilitate transmembrane protein
associations and play a role in mediating formation of the
US3-MHC class I heavy complex.
Materials and methods
Plasmids
US3 expression plasmids were generated by amplifying
US3 sequences from either p516 or p517 (kindly provided
by A. Colberg-Poley, Children’s Hospital, Washington,
DC), which contain US3 cDNAs corresponding to the
unspliced or the singly spliced US3 transcript, respectively
(Tenney et al., 1993). The resulting PCR amplimers were
digested with BamHI and HindIII and inserted into pRevTRE
(Clontech Laboratories, Inc.). pBJ371 contains the en-
tire US3 open reading frame generated using oligonucleo-
tides 211 (5 CAGGATCCTTCTCAGCGAAGCACTGC
3) and 212 (5 AATGAAGCTTGTGTTAGAGTCCG-
TACCTTG 3). pBJ391 contains the US3 open reading
frame from amino acids 1 to 155, deleting the transmem-
brane domain and carboxyl-terminal tail and was con-
structed using oligonucleotides 134 (5 AATGGATCCTC-
GAGTGTTGAGGTCCGTACCTTG 3) and 225 (5
TTTAAGCTTCCCAATTGTCGCTCTCATG 3). pBJ392
expresses the US3 open reading frame from amino acids 1
to 178, deleting the COOH-terminal cytoplasmic tail, and
was constructed using oligonucleotides 134 and 226 (5
TTTAAGCTTCCCACGGTCAGGAGCACAAGAAC 3).
pBJ382 and pBJ383 express mutated versions of the 22-kDa
US3 protein, with lysines residues 124 and 125 mutated to
valines and cysteine44 mutated to serine, respectively. Site-
directed mutagenesis was performed using the Chameleon
mutagenesis kit (Stratagene); pBJ371 as the template and
oligonucleotides pairs 209 (5 GGAACACACGCG-
GCATATACCACGGGGTCTCCCCACCTCG 3) and 210
(5 CGAGGTGGGGAGACCCCGTGGTATATGCCGC-
GTGTGTTCC 3) or 207 (5 CGAGTGGAGGAGAA-
CCAAAGCTGGTTCCATATGGG 3) and 208 (5
CCCATATGGAACCAGCTTTGGTTCTCCTCCACTCG
3).
Plasmids expressing US3-EGFP fusion proteins were
generated using PCR and p516 as the template for pBJ521,
324, 524 and 523, and p517 as the template for pBJ323 (Liu
et al., 2002). The following primer pairs were used to
generate the amplimers; pBJ521, 133 (5 CAGGAATTCT-
CAGCGAAGCACTGC 3), and 259 (5 CCAGGATC-
CATAATAAATCGCAGACGGGGCGC 3); and pBJ524,
133, and 271 (5 CCAGGATCCCAATTGTCGTCTCT-
CATGC 3). Amplimers were digested with BamHI and
HindIII and inserted into matching sites in pEGFP-iresNeo
(Clontech). Fusion proteins were expressed from the result-
ing constructs as follows: pBJ521, pUS322kDa-EGFP;
pBJ323, pUS317kDa-EGFP; pBJ324, COOH-pUS322kDa-
EGFP; pBJ523, TM pUS322kDa-EGFP; pBJ517,
pUS322kDa C3S44-EGFP; and pBJ520, pUS322kDaKK3VV124,125-
EGFP.
Generation of cell lines
pBJ317, pBJ391, pBJ392, pBJ382, and pBJ383 were
transfected into PT67 packaging cells (Clontech) using cal-
cium phosphate. Two to three days after transfection, cells
containing the plasmids were selected using 0.2 mg/ml
hygromycin. Virus stocks were harvested from confluent
cultures as directed by the manufacturer. The retrovirus
stocks were then used to infect HeLa Tet-on cells (Clon-
tech); hygromycin and G418 were used to select cells con-
taining the integrated retroviruses. The resulting cell lines
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were characterized by Southern blot analysis to confirm the
presence of the integrated retrovirus (data not shown).
Northern blot analysis, analyzing the HeLa tet-on cells for
induction of US3 transcripts, was also performed and dem-
onstrated that approximately equivalent levels of US3 tran-
scripts were synthesized in the presence of doxycycline
(data not shown).
Protein labeling and immunoprecipitation
US3 expression in the HeLa tet-on cells was induced
with 1 g/ml doxycycline 2 days prior to metabolic labeling
of the cell proteins with [35S]methionine. For labeling, cell
monolayers were first washed with methionine–cyteine-free
medium; proteins were then labeled by incubating mono-
layers in methionine–cysteine-free medium containing 200
uCi of 35Met-35Cys (Easy Tag Express, NEN Life Science
Products, Boston, MA) for 30 min. The radioactive label
was chased in the appropriate dishes by the addition of
complete media and 1-h incubation at 37°C. Cells were then
rinsed with cold PBS, lysed, and immunoprecipitated using
the monoclonal antibody W6/32 (Sigma, St. Louis, MO) as
described (Liu et al., 2002).
Fluorescence microscopy
EGFP-fusion proteins were detected in transfected cells
using a FITC filter. The ER was labeled using a monoclonal
antibody to protein disulfide isomerase (Stressgen, Victoria,
BC, Canada). Primary antibody binding was detected using
Texas-red-conjugated goat anti-mouse antisera (Molecular
Probes, Eugene, OR) as the secondary antibody. Immuno-
fluorescence was performed as described (Colberg-Poley et
al., 2000). Nuclei were stained with 46-diamidino-2-phe-
nylin-dole (DAPI, Molecular Probes) as recommended by
the manufacturer. Cells were visualized using a Nikon mi-
croscope with the appropriate fluorescence filters; images
were captured using a SPOT digital camera.
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